We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Special Issue: Resistance to Targeted Therapies in Human Cancer.
- Authors
Lee, Tae-Won; Choi, Hee-Joo; Lee, Kyung-Min; Lee, Jeong-Yeon
- Abstract
A huge number of effective target therapies have been developed over the past few decades for cancer treatment, which in turn have had the effect of improving the patients' prognoses. Finally, the combination treatment of KAS-08 with cGAMP elicited a significant anti-tumor effect compared to single cGMP treatment in vivo. Among the multi-kinase inhibitors, sunitinib, which targets vascular endothelial growth factor (VEGF) and other tyrosine kinases, is currently used as a first-line therapy for the treatment of renal cell carcinoma (RCC). Taylor and colleagues [[1]] comprehensively reviewed the different types of small-molecule inhibitors that are currently available as cancer-targeted drugs, such as selective kinase inhibitors and nonselective multi-kinase inhibitors, and their known resistance mechanisms.
- Subjects
CANCER treatment; SMALL molecules; CANCER cell growth; IMMUNE checkpoint proteins
- Publication
Biomedicines, 2023, Vol 11, Issue 2, p414
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines11020414